Literature DB >> 2230850

Treatment of chronic relapsing inflammatory demyelinating polyneuropathy by cyclosporin A and plasma exchange. A case report.

H Hefter1, K B Sprenger, G Arendt, D Hafner.   

Abstract

A patient with chronic relapsing inflammatory demyelinating polyneuropathy was successfully treated with plasma exchanges and cyclosporin A (CsA). Dynamometric measurements of hand force during the time of CsA treatment showed a highly significant correlation between hand force and CsA blood levels. The largest influence of CsA on hand force occurred 11-13 days after CsA uptake.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2230850     DOI： 10.1007/bf00314752

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  14 in total

1.  Remission of Sézary's syndrome with cyclosporin A. Mild capillary leak syndrome as an unusual side effect.

Authors:  D Ramon; I Betlloch; A Jimenez; R Botella; A Castells; V Alberola
Journal:  Acta Derm Venereol       Date:  1986       Impact factor: 4.437

2.  Cyclosporine therapy in chronic inflammatory demyelinating polyradiculoneuropathy--a preliminary report of clinical results in two patients.

Authors:  P J Jongen; E M Joosten; J H Berden; A A Gabreëls-Festen
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  Continuous membrane plasma separation: three years of experience.

Authors:  K B Sprenger
Journal:  Life Support Syst       Date:  1983 Oct-Dec

4.  Cyclosporin A treatment in a case of relapsing polychondritis.

Authors:  K L Svenson; R Holmdahl; L Klareskog; L Wibell; O Sjöberg; G B Klintmalm; H Boström
Journal:  Scand J Rheumatol       Date:  1984       Impact factor: 3.641

5.  Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination.

Authors:  P K Thomas; R W Walker; P Rudge; J A Morgan-Hughes; R H King; J M Jacobs; K R Mills; I E Ormerod; N M Murray; W I McDonald
Journal:  Brain       Date:  1987-02       Impact factor: 13.501

6.  Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  S Kolkin; N S Nahman; J R Mendell
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

7.  Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.

Authors:  R S Tindall; J A Rollins; J T Phillips; R G Greenlee; L Wells; G Belendiuk
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

8.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

9.  Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor.

Authors:  K V Toyka; R Augspach; H Wiethölter; U A Besinger; F Haneveld; U G Liebert; K Heininger; G Schwendemann; K Reiners; B Grabensee
Journal:  Muscle Nerve       Date:  1982 Jul-Aug       Impact factor: 3.217

Review 10.  Humoral factors in peripheral nerve disease.

Authors:  K V Toyka; K Heininger
Journal:  Muscle Nerve       Date:  1987 Mar-Apr       Impact factor: 3.217
View more
  5 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.

Authors:  W Mahattanakul; T O Crawford; J W Griffin; J M Goldstein; D R Cornblath
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

Review 3.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

4.  Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin.

Authors:  M Odaka; M Tatsumoto; K Susuki; K Hirata; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.